1. Home
  2. QDEL vs ANAB Comparison

QDEL vs ANAB Comparison

Compare QDEL & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

N/A

Current Price

$16.22

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

ANAB

AnaptysBio Inc.

N/A

Current Price

$63.01

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QDEL
ANAB
Founded
1979
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2022
2015

Fundamental Metrics

Financial Performance
Metric
QDEL
ANAB
Price
$16.22
$63.01
Analyst Decision
Hold
Strong Buy
Analyst Count
4
10
Target Price
$32.75
$72.60
AVG Volume (30 Days)
1.2M
491.1K
Earning Date
05-06-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
45.35
91.02
EPS
N/A
N/A
Revenue
$2,730,200,000.00
$234,603,000.00
Revenue This Year
$3.51
N/A
Revenue Next Year
$3.86
$33.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
157.01
52 Week Low
$15.08
$15.40
52 Week High
$37.24
$68.39

Technical Indicators

Market Signals
Indicator
QDEL
ANAB
Relative Strength Index (RSI) 32.27 58.51
Support Level N/A $43.67
Resistance Level $30.65 $68.39
Average True Range (ATR) 1.18 3.72
MACD -0.06 -0.22
Stochastic Oscillator 16.64 63.65

Price Performance

Historical Comparison
QDEL
ANAB

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: